Clinical Trial Update: Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a vaccine made from lethally irradiated glioma cells mixed with GM-K562 cells in patients undergoing craniotomy for recurrent glioma. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Vaccination with lethally irradiated glioma cells mixed with GM-K562 cells

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Glioma | Phase 1 | Status: COMPLETED